Novo Nordisk and Eli Lilly sought to dismiss claims that the companies deceived the medical community and consumers about the safety of weight loss medications, such as Ozempic. More than 1,300 cases are pending against the companies in multidistrict litigation (MDL) over the drug’s glucagon-like peptide-1 receptor agonists (GLP-1 Ras). That number is expected to[…] Read More
